Drugs / REPEVAX
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 36 trials · 3 met primary | ||||||
| Phase 3 | NCT01287949 | Jan 2011 → May 2012 | diphtheria, pertussis, poliomyelitis, tetanus | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT01249183 | Oct 2010 → Sep 2011 | diphtheria, pertussis, poliomyelitis, tetanus | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT01073293 | Apr 2010 → Jun 2011 | human papilloma virus infection | Merck Sharp & Dohme LLC | Completed | Met primary |
| Phase 3 | NCT00928785 | Jul → Dec 2009 | — | Sanofi Pasteur, a Sanofi Company | Completed | Met primary |
| Phase 3 | NCT00400309 | Jun 2006 → Feb 2007 | — | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT00337428 | May 2006 → May 2007 | diphtheria, neoplasm, pertussis, poliomyelitis +1 | Merck Sharp & Dohme LLC | Completed | Met primary |
| Phase 41 trial | ||||||
| Phase 4 | NCT00304265 | Mar → Oct 2006 | diphtheria, pertussis, poliomyelitis, tetanus | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Comparator or background therapy4 trials | ||||||
| Phase 2 | NCT01323270 Comparator | Mar 2011 → Oct 2012 | meningitis, meningococcal infection | Pfizer | Completed | Met primary |
| Phase 3 | NCT01245049 Comparator | Apr 2011 → Mar 2012 | diphtheria, poliomyelitis, tetanus | GlaxoSmithKline | Completed | Met primary |
| Phase 4 | NCT02145624 Comparator | Oct 2014 → Jun 2017 | — | Public Health England | Completed | No outcome recorded |
| Phase 4 | NCT02526394 Comparator | Sep 2013 → Mar 2017 | meningococcal meningitis, pertussis | Public Health England | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | REPEVAX | “1 dose (0.5 mL) of VAXIGRIP and 1 dose (0.5 mL) of REPEVAX in 2 separate injections sites (1 on each arm)” NCT01249183 ↗10“Diphtheria, Tetanus, Acellular Pertussis and Poliomyelitis Vaccine (REPEVAX)” NCT01287949 ↗ “Repevax + Meningitec” NCT02526394 ↗ |
| Known as | dTap-IPVR | “dTap-IPVR (Repevax, Sanofi Pasteur)” PMID 29576304 ↗ Mar 2018 |
| Modality | Vaccine | “REPEVAX® (Tdap-IPV: combination diphtheria, tetanus and acellular pertussis with inactivated poliomyelitis vaccine)” NCT00304265 ↗ |
| Route | Intramuscular | “0.5 mL, Intramuscular” NCT00304265 ↗ |